New data says medical cannabis is actually helping autistic adults sleep and stress less

Researchers out of King's College London, Imperial College London, and two NHS trusts pulled 18 months of data from the UK Medical Cannabis Registry on 130 autistic adults who'd been prescribed cannabis-based medicinal products, and the numbers held up better than a lot of us would've guessed going in.

Using the same standardized tools clinicians already trust — the GAD-7 for anxiety, a Sleep Quality Scale, and the EQ-5D-5L for overall quality of life — the study tracked real, sustained improvement over the full 18 months, not just a short-term bump. Quality-of-life scores climbed from 0.43 to 0.51 on the EQ-5D-5L index, and patients kept reporting the improvement held up on repeat surveys.

It wasn't all smooth, and the researchers didn't pretend otherwise: 25 of the 130 participants (about 19%) logged 232 adverse events between them, mostly mild to moderate. And there was no control group, so this is an association, not proof that the cannabis caused the improvement on its own — the study's authors are explicit that a proper randomized trial is still the next step.

Still, for a population where medication options are often limited and side-effect-heavy, 18 months of consistent, patient-reported improvement in anxiety and sleep is a real data point, not just an anecdote. It's exactly the kind of long-horizon, registry-based evidence that moves the conversation about medical cannabis for autism from message-board testimonials toward something a doctor can actually point to.